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A comparison of the polymorphic forms of 3 commercial sources of fusidic acid using FTIR and XRPD techniques has been
performed in this study. It has been demonstrated that polymorphic Forms I and III are currently available on the commercial
market. The influence of the observed polymorphism on the stability of the drug substance in bulk form has been investigated
through stability and stress testing according to current ICH guidelines. Significant differences were detected between commercial
sources with regard to the stability of the bulk substance under photolytic and humidity stress conditions.When properly packaged
in an inert atmosphere, fusidic acid from all 3manufacturers showed a comparable stability.The effects of the observed polymorphic
differences on the intrinsic dissolution rate of the drug substance and its in vitro release from themarketed drug product Fusicutan
plus Betamethasone cream have been investigated. Results indicated that the release rate of the drug substance is similar for
polymorphic Forms I and III, allowing both forms to be used during manufacture without affecting the safety or efficacy of the
drug product.
1. Introduction
Fusidic acid (FA, Figure 1(a)) is one of 18 naturally occurring
triterpene compounds of fungal origin [1] which collectively
make up the Fusidane group of antibiotic substances [2]. It
is the most potent member of this group and is, to date,
the only representative to have been used clinically [2]. It
was first isolated fermentatively in the early 1960s from the
fungus Fusidium coccineum [3], with the description of a
complete chemical synthesis following some 20 years later
[4]. FA is mainly used in the treatment of Gram-positive bac-
terial infections (e.g., infected atopic dermatitis, Figure 1(b)),
particularly those caused by Staphylococcus species [2, 5, 6],
and functions by binding to prokaryotic elongation factor
G (EF-G), effectively stalling the elongation step of bacterial
protein synthesis [7–9]. At clinically relevant concentrations,
the substance has a bacteriostatic effect but canwork as bacte-
ricidal at higher concentrations [10].The past decade has seen
renewed interest in this drug as a treatment for methicillin-
resistant Staphylococcus aureus (MRSA, Figure 1(c)) [11–16]
which can in part be attributed to its low toxicity and to
the low incidence of resistance to FA in relevant bacterial
populations [14, 15].
FA is known to demonstrate polymorphism, with 4 crys-
talline forms (I–IV) described to date in relevant literature
[17–19]. It has been well documented that polymorphs of
the same drug substance can possess different solubility
properties which may lead to variations in local and/or
systemic bioavailability and stability [20–23].This can present
problems when a pharmaceutical manufacturer needs to
change supplier of an active pharmaceutical ingredient (API)
or add a second supplier in order to ensure a constant supply
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Figure 1: (a) Chemical structure of fusidic acid, (b) an example of infected atopic eczema of the forearm, and (c) a scanning electron
micrograph of Staphylococcus aureus.
of a particular drug substance. In such cases, comparative
characterisation studies of the crystalline structure, solubility,
and in vitro release properties of the API from the drug
product, as well as associated stability studies, must be
performed.
Despite the fact that FA has been on themarket for several
decades [3], polymorphism in this substance has only been
documented in more recent times [17–19] and to date no
report has focused on the release rate and stability of different
polymorphs of FA from topical pharmaceutical formulations.
Strict legislative requirements are in place with regard to the
use of different polymorphic drug forms in pharmaceutical
products [24]. Thus, the goal of the current study is to assess
the effects of polymorphism in commercial sources of FA
on (i) the stability of the bulk drug substance and (ii) its
in vitro release rate from a marketed topical pharmaceutical
dosage form.This information is of critical importance when
considering whether FA from different commercial sources
can be used interchangeably in semisolid pharmaceutical
preparations without significant implications for the safety
and efficacy of the product.
2. Materials and Methods
2.1. Reagents. Fusidic acid of Ph. Eur. quality was purchased
from Ercros SA (Madrid, Spain, Manufacturer A), Joyang
Laboratories (Jiangsu, China, Manufacturer B) and OJSC
Biosintez (Penza, Russia, Manufacturer C). Gradient grade
methanol and acetonitrile were purchased from VWR Inter-
national GmbH (Darmstadt, Germany). Purified water was
obtained from the in-house purification system at mibe
GmbH Arzneimittel (Brehna, Germany). Phosphoric acid
(85%m/m, analysis grade, 𝑑 = 1.71 g/ml) was purchased
from Merck (Darmstadt, Germany). All cream samples were
provided by mibe GmbH Arzneimittel (Brehna, Germany).
2.2. Instrumentation and Experimental Procedures
2.2.1. Stability Studies and HPLC Analysis. Stability studies
of micronised and nonmicronised FA from each manufac-
turer were performed in Binder KBF 720 stability chambers
(Binder Inc., Tuttlingen,Germany) according to relevant ICH
guidelines. The aim of the studies was to investigate if the
polymorphicmodification of FA influences the stability of the
bulk drug substance during storage. It should be noted that
the particle size distributions of FA from each manufacturer
were comparable. Samples comprising 5 g of drug substance
stored under a nitrogen atmosphere in a suitably sealed
polyethylene bag, which was further packaged in a heat
sealed aluminium sachet, were placed on stability under the
conditions of 5 ± 3∘C, 25∘C/60% relative humidity (RH),
30∘C/65%RH, and 40∘C/75%RH for 24, 24, 12, and 6months,
respectively.
HPLC experiments were performed with Shimadzu
Prominence HPLC Systems (Shimadzu, Japan). The sys-
tems were equipped with a binary pump (LC-20AD), a tem-
perature-controlled autosampler (SIL-20ACHT), a temper-
ature-controlled column compartment (CTO-20AC), and
an online degasser (DGU-20A
5
). A DAD detector (SPD-
M20A) was employed. The software packages used were
Shimadzu LCsolution version 1.24 SP1 and Shimadzu Class-
VP version 6.14 SP2A. Samples were prepared and analysed
using the stability-indicating procedure described in the
European Pharmacopeia (Ph. Eur.) monograph for fusidic
acid hemihydrate [25].
2.2.2. XRPD/ATR-FTIR/SEM. XRPD analysis was performed
using a Bruker D8 Advance (Bruker, Massachusetts, USA)
with parallel beam geometry and a Cu/Cu K𝛼 radiation
source. Samples were scanned from 5∘ to 60∘2𝜃 at a step
size of 0.03∘ and a step time of 1 s using a LynxEye detec-
tor. Data was collected and analysed using Bruker Diffrac
Plus XRD software. ATR-FTIR analysis was performed on
a Perkin-Elmer SpectrumOne spectrophotometer (Perkin-
Elmer, Massachusetts, USA). Scanning electron micrographs
were obtained using a Hitachi 3200N SEM instrument
(Hitachi, Tokyo, Japan).
2.2.3. Intrinsic Dissolution/In Vitro Diffusion Test. Intrinsic
dissolution experiments were performed using an ERWEKA
DT800 dissolution apparatus (ERWEKA, Heusenstamm,
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Germany) equipped with 6 rotating cylinders as described in
Ph. Eur. 2.9.29. A rotation speed of 50 rpm and a medium
comprising 500ml of 0.01M sodium hydroxide were used.
Pellets were prepared by compacting 100mg of sample at a
pressure of 5 tonnes using a suitable hydraulic press. The
experiment was performed at 37∘C.
Suitable conditions were chosen which would lead to
approximately 10–20% release of the drug substance over a
reasonable time period. For the final analysis, samples were
taken at 10-, 20-, 30-, 40-, 50-, and 60-minute intervals with
a total release of ca. 15% of the drug. Samples were measured
by UV-visible spectrophotometry at a wavelength of 240 nm
using a Specord 205 spectrophotometer (Analytik Jena, Jena,
Germany). The intrinsic dissolution rate (mg/ml/cm2) was
calculated as the slope of the best-fitting line (mg/min)
divided by the surface area of the drug substance (cm2).
In vitro diffusion experiments were performed using a
suitable Franz cell apparatus (Hanson Research, Chatsworth,
USA) comprising 6 jacketed, diffusion cells connected by
suitable tubing to a heated reservoir of fluid which was
kept at a constant temperature of 32∘C using a ScanVac
SHC 2000 temperature bath (Labogene, Lynge, Denmark).
Each diffusion cell contained a magnetic stirring bar and
approximately 7ml of a collector medium comprising a
mixture of 50 : 50 methanol/water (v/v). Porafilmembranes
(Macherey-Nagel, Du¨ren, Germany) made from regenerated
cellulose and having a porosity and diameter of 0.45 𝜇m
and 25mm, respectively, were employed in all tests. 300mg
of the cream sample were used for each diffusion cell.
Sampling was performed at intervals of 60, 120, 180, 240,
and 300 minutes and the samples were measured using a
validated HPLC procedure. The HPLC method is comprised
of a Spherisorb ODS 2, 150 × 4.6mm column packed with
5 𝜇m particles and a mobile phase comprising methanol,
10 g/L phosphoric acid, purified water, and acetonitrile at
a ratio of 10 : 20 : 20 : 50 v/v/v/v. The flow-rate, column-oven
temperature, and detector wavelengthwere 2.0ml/Min, 25∘C,
and 235 nm, respectively. The method was run isocratically
for 15 minutes and an injection volume of 15 𝜇l was used.
3. Results and Discussion
3.1. FTIR and XRPD Analysis. The characterisation of FA
has been described in a number of patents as well as in
the mainstream scientific literature. FTIR spectra and XRP
diffractograms of each of the polymorphic forms of FA
have previously been described [17–19]. The most significant
differences between the FTIR spectra of these forms are
observed in the region 1650 cm−1 to 1750 cm−1. Form I shows
a single stretching band at ≈1720 cm−1, whilst Form II shows
a band at ≈1720 cm−1 and an additional stretch at ≈1697 cm−1
which is not present in the other forms. Form III shows two
very distinct bands at approximately 1748 cm−1 and 1688 cm−1
which are also not present in the other forms. A comparison
of the literature data with the FTIR data of FA from the
commercial samples shows that FA from Manufacturer A is
of Form III, FA from Manufacturer C is of Form I, and FA
from Manufacturer B is comprised predominantly of Form
III but is not of pure crystalline form. It contains significant
quantities of either Form I or Form II, which can be seen
by the presence of an extra absorption band at ≈1720 cm−1
(Figure 2).
Powder X-ray diffraction analysis of FA from Manufac-
turers A, B, and C (Figure 3) demonstrates that A and B are
of similar crystal form (Form III), since both diffractograms
are comparable for all significant reflexes. In contrast, the
diffractogram of FA from Manufacturer C shows significant
differences to A and B and is comparable with the literature
data for Form I. The XRPD data agrees with the results of
the FTIR analysis. Scanning electronmicrographs of FA from
each of the manufacturers show differences in morphology
(Figure 3).
3.2. Stability Studies
3.2.1. Stability Studies. The study results (Figures 4(a), 4(b),
and 4(c)) indicate that the stability of FA is temperature
dependent. The greatest stability is observed at 5 ± 3∘C,
with the stability decreasing with increasing temperature.
No significant difference in stability was observed between
polymorphic Form I (Manufacturer C) and Form III (Manu-
facturers A and B) under ICH conditions. The data indicated
that micronisation of the API has a negative effect on the
stability of FA, as demonstrated by the higher levels of
impurities observed in this material as compared to the
nonmicronised API. This is likely due to the reduction of
the particle size and corresponding significant increase of
the specific surface area of the substance after micronisation.
XRPD and FTIR analysis confirmed that the polymorphic
form of FA does not change during micronisation or storage.
3.2.2. Stress Tests. The ICH stability studies described above
demonstrate that there are no significant differences in
stability between polymorphic Forms I and III under the
chosen conditions. However, under harsher conditions both
light and humidity give rise to degradation in FA. The pho-
tostability of FA was examined according to ICH guideline
Q1B, whereby the samples were illuminated for 1.2million lux
hours with energy of 200 watt hours/m2. The humidity test
was performed by placing fusidic acid in an open container
and storing at 60% relative humidity for 6 months. The
results of both tests indicated that FA from Manufacturer B
was significantly less stable under these conditions than FA
from either of the 2 other manufacturers (Figure 4(d)).These
results are however unlikely to be relevant for the stability
of the drug substance in a medicinal product since the
productwould never be exposed to such harsh environmental
conditions during manufacture, transport, or storage.
3.3. Intrinsic Dissolution Rate. In order to compare the
solubility properties of FA from each of the 3 manufacturers,
the intrinsic dissolution rates of each sample were analysed
according to Ph. Eur. 2.9.29 using the rotating cylinder
apparatus. Preliminary experiments were performed in order
to investigate the effect of rotation speed (50, 100, and
150 rpm) and press tonnage (3, 5, and 7 tonnes) on the release
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Figure 2: FTIR spectra of FA fromManufacturers A, B, and C demonstrating major differences in the region 1600 cm−1 to 1800 cm−1. Spectra
(a) and (b) correspond to polymorphic Form III and showmajor differences as compared to spectrum (c) which shows polymorphic Form I.
rate of the substance. The rotation speed was found to have a
significant effect, with an increased rotation speed leading to
a more rapid release rate. The press tonnage had no effect on
the release rate. FTIR spectra of the samples taken before and
after pressing showed that no phase change occurred during
the preparation of the pellets.
The measured release rates were 0.42, 0.36, and
0.30mg/min/cm2 forManufacturersA, B, andC, respectively.
Statistical analysis of the data was performed using a
nonparametric confidence interval procedure related to
the Mann–Whitney rank test [26]. The analysis showed
no significant difference between the IDR profiles of FA,
indicating that the samples have comparable intrinsic
dissolution rates. This is in good agreement with previous
literature results which found similar intrinsic dissolution
rates for Forms I, II, and III [19].
3.4. InVitro Release Profile fromFusicutan plus Betamethasone
Cream. The results of the intrinsic dissolution tests indicated
that the investigated samples show comparable dissolution
rates in the model system used for this test. This data
provides useful clues about the comparability of the solubility
properties of the measured samples. It can however not easily
be extrapolated to the release rate of the drug substance
from a semisolid drug product. In semisolid systems, the
drug substance is very often suspended in a complex matrix,
with only a fraction of the total quantity of drug substance
being dissolved in solution. In order to compare the release
rates of drug substances from semisolid preparations, an in
vitro penetration test is often employed. One of the most
commonly employed versions of such a test uses a vertical
diffusion cell, or Franz cell, comprising a jacketed, vertical
diffusion cell connected by appropriate tubing to a heated
reservoir of fluid which is continuously pumped around
the system to ensure a constant temperature of 32∘C, thus
mimicking the temperature at the external skin surface.
This model was employed in the present case. Quantitative
analysis was performed using a validated HPLC procedure
with UV detection.
In order to demonstrate the discriminatory power of
the procedure, that is, the ability of the procedure to detect
differences in the release rates of API from different cream
formulations, a batch of creamwas preparedwhich contained
nonmicronised FA (note: FA is normally present in the
finished formulation in its micronised form). The release
rate for this batch was significantly slower than for the test
batches, which all contained micronised material. The slower
release rate can be attributed to the larger particle size of
the FA crystals which take longer to dissolve. This indicates
that the analytical procedure is capable of discriminating
between batches with different release rates. Figure 5 shows
the results of the in vitro diffusion test. A statistical analysis
of the release rates of FA from each of the test batches of
cream was performed using the same procedure as described
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Figure 3: Scanning electron micrographs and X-ray powder diffractograms of FA from Manufacturers A (micronised) and B and C (both
nonmicronised). Manufacturers A and B show identical reflexes corresponding to polymorphic Form III. The diffractogram of FA from
Manufacturer C shows major differences to A and B and corresponds to polymorphic Form I as described in the literature.
in Section 3.3 [26]. The release rates were not significantly
different according to this test.
4. Conclusions
The results of the present study indicate that there are at
least 2 polymorphic forms of fusidic acid (I and III) currently
available on the commercial market. Under refrigerated,
real-time, and accelerated stability conditions, the API from
all 3 sources employed in this study were found to have
comparable stabilities when packaged under an atmosphere
of nitrogen in an air-tight, light-protective container. The
stability of FA was found to be temperature dependent
with the greatest stability being observed at 5∘C ± 3∘C.
Micronisation was found to reduce the stability of FA as
compared to nonmicronised material. Under stress con-
ditions, the API from Manufacturer B was found to be
significantly less stable than material from either of the other
2 sources. This instability is unlikely to be related directly
to the stability of the predominant polymorphic form of the
material (Form III), since Manufacturer A is of the same
form and is stable. The instability may be related to the
fact that the material is not of pure polymorphic form. The
current study demonstrated that material fromManufacturer
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Figure 4: Results of stability studies of FA performed at 5∘C ± 3∘C (a), 25∘C/60% RH (b), and 40∘C/75% RH (c) as well as under photolytic
stress conditions as described in ICH Q1B (d).
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Figure 5: In vitro release profiles of FA from Fusicutan plus
Betamethasone cream showing statistically comparable release rates
for FA from all 3 drug substance manufacturers.
B contains substantial quantities of another polymorphwhich
may influence the overall stability of the material. This issue
was however not within the scope of the current study and
requires further investigation.
The intrinsic dissolution rates of each of the drug samples,
as well as their in vitro diffusion rates from the marketed
topical product Fusicutan plus Betamethasone, were analysed
and found to be statistically comparable. The data indicates
that polymorphic Forms I and III found in FA samples
from the investigated manufacturers have similar solubility
properties and can be used interchangeably in semisolid drug
product formulations without affecting the safety and efficacy
of those formulations.
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